1.
Lukens AK, Ross LS, Heidebrecht R, et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc Natl Acad Sci U S A. 2014;111(2):799-804. doi:10.1073/pnas.1320886110.
1.
Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452-65. doi:10.1158/2159-8290.CD-13-0646.
1.
Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546-53. doi:10.1158/2159-8290.CD-13-0353.
1.
Wang J, Mikse O, Liao RG, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34(17):2167-77. doi:10.1038/onc.2014.161.
1.
Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616-20. doi:10.1038/nature13393.
1.
Shaul YD, Freinkman E, Comb WC, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158(5):1094-109. doi:10.1016/j.cell.2014.07.032.
1.
Bar-Nur O, Brumbaugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 2014;11(11):1170-6. doi:10.1038/nmeth.3142.
1.
MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721-31. doi:10.1038/nrd4627.